Products
Online Inquiry
Our Products Cannot Be Used As Medicines Directly For Personal Use.
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
Perifosine
Cat No.
CEI-0114
Description
Perifosine can inhibit Akt with IC50 og 4.7 uM.
Alias
KRX-0401
CAS No.
157716-52-4
Molecular Weight
461.66
Purity
>99%
Storage
2 years at -20centigrade Powder
Synonyms
KRX-0401
Targets
Akt
Molecular Formula
C25H52NO4P
Chemical Name
Piperidinium, 4-[[hydroxy(octadecyloxy)phosphinyl]oxy]-1,1-dimethyl-, inner salt
Solubility
DMSO
In vitro
Perifosine (D-21266, KRX-0401) is an analogue of miltefosine. Perifosine, a bioavailable ALK (Alkylphospholipids)showed antiproliferative properties on the cell cycle kinetics of immortalized keratinocytes (HaCaT) as well as head and neck squamous carcinoma cells with an IC50 of 0.6-8.9 uM. Perifosine induced both G(1)-S and G(2)-M cell cycle arrest at the concentration of 20 uM, together with p21(WAF1) expression in both p53 wild-type and p53(-/-) clones.Perifosine blocks cell cycle progression of head and neck squamous carcinoma cells at G(1)-S and G(2)-M by inducing p21(WAF1), irrespective of p53 function. Perifosine causes dose-dependent inhibition of protein kinase B/Akt phosphorylation and thus activation at concentrations causing growth inhibition of PC-3 prostate carcinoma cells. perifosine decreases the plasma membrane localization of Akt, and this is substantially relieved by MYR-Akt along with relief of downstream drug effect on induction of p21(WAF1/CIP1). Perifosine does not directly affect phosphoinositide 3-kinase (PI3K), phosphoinositide-dependent kinase 1, or Akt activity at concentrations inhibiting Akt phosphorylation and membrane localization.
Download
Download Datasheet